Viridian Therapeutics, Inc.VRDNNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+49.8%
5Y CAGR+64.3%
Year-over-Year Change
Research and development spending
3Y CAGR
+49.8%/yr
vs +35.0%/yr prior
5Y CAGR
+64.3%/yr
Recent deceleration
Acceleration
+14.8pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
12x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $338.93M | +42.3% |
| 2024 | $238.25M | +49.1% |
| 2023 | $159.76M | +58.3% |
| 2022 | $100.89M | +77.4% |
| 2021 | $56.89M | +101.0% |
| 2020 | $28.30M | -18.7% |
| 2019 | $34.79M | +14.4% |
| 2018 | $30.42M | +55.0% |
| 2017 | $19.62M | +2109.8% |
| 2016 | $888000.00 | - |